Quality of life in oncology in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma Review article
Article Sidebar
Published:
Dec 30, 2011
Keywords:
advanced renal cell carcinoma, pharmacotherpay, quality of life, toxcity
Main Article Content
Abstract
Introduction of molecularly targeted agents into clinical practice has led to marked progress in pharmacotherapy of advanced renal cell carcinoma. There have been six drugs of the therapeutic class registered to date. Further registration is expected next year. Targeted therapy proved to prolong time to disease progression of renal cell cancer. If administered sequentially they prolong overall survival as well. The treatment usually tends to last. The disease gains status of chronic illness. Molecular predictive factors are not available and decisions regarding specific therapeutic choices are based on clinical factors. Due to all aforementioned the toxicity profile and related quality of life should be of special interest. The article is the discussion of methodology of quality of life clinical trials, the data collection, data analysis and review of current knowledge regarding this issue in context of treatment of renal cell carcinoma based on molecularly targeted therapy.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Żołnierek J, Wysocki P. Quality of life in oncology in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma. OncoReview [Internet]. 2011Dec.30 [cited 2024Nov.23];1(4(4):293-0. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/287
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Guyatt G.H., Feeny D.H., Patrick D.L.: Measuring health-related quality of life. Ann. Intern. Med. 1993; 118: 622-9.
2. Roila F., Cortesi E.: Quality of life as primary end point in oncology. Ann. Oncol. 2001; 12(supl.): S3-S6.
3. Feld R.: Endpoints in cancer clinical trials: Is there a need for measuring quality of life? Support Care Cancer 1995; 3: 23-7.
4. Casali P., Licitra L., Costntini M. et al.: Quality of life assessement and clinical decision-making. Ann. Oncol. 1997; 8: 1207-11.
5. Anderson R.T., Aaronson N.K., Bullinger M. et al.: A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research. Pharmacoeconomics 1996; 10: 336-55.
6. Maguire P., Selby P.: Assessing quality of life in cancer patients. B. J. Cancer 1989; 60: 437-40.
7. Bonomi A.E., Cella D.F., Hahn E.A. et al.: Multilingual translation of the Functional Assessement of Cancer Therapy (FACT) quality of life measurement system. Qual. Life Res. 1996; 5: 309-20.
8. Cella D., Hernandez L., Bonomi A.E. et al.: Spanish language translation and initial validation of the functional assessement of cancer therapy quality-of-life instrument. Med. Care 1998; 36: 1407-18.
9. Cella D.F., Tulsky D.S., Gray G. et al.: The Functional Assessement of Cancer Therapy scale: Development and validation of the general measure. J. Clin. Oncol. 1993; 11: 570-9.
10. Luckett T., King M.T., Butow P.N. et al.: Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann. Oncol. 2011; 22: 2179-90.
11. Cohen J.: Statistical power analysis for the behavioral Sciences. Wyd. 2. Materiały akademickie 1998.
12. Cella D.: Manual of the Functional Assessement of Chronic Illness Therapy (FACIT Scales), Version 4.1998. Evanston Northwestern Healthcare&Northwestern University Press, Center on Outcomes, Research and Education.
13. Brucker P.S., Yost K., Cashy J. et al.: General population and cancer patient norms for the Functional Assessement of Cancer Therapy – General (FACT-G). Eval. Health Prof. 2005; 28: 192-211.
14. Brazier J., Jones N., Kind P.: Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual. Life Res. 2004; 2: 169-80.
15. De Boer A.G., van Lanschott J.J., Stalmeier P.F. et al.: Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual. Life Res. 2004; 13: 311-320.
16. Rabin R., de Charro F.: EQ-5D: A measure of health status from the EuroQoL Group. Ann. Med. 2001; 33: 337-43.
17. Cella D., Yount S., Du H. et al.: Development and validation of the Functional Assessement of Cancer Therapy – Kidney Symptom Ondex (FKSI). J. Support Oncol. 2006; 4: 191-9.
18. Motzer R.J., Hutson T.E., Tomczak P. et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 3584-90.
19. Cella D., Li J.Z., Cappelleri J.C. et al.: Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J. Clin. Oncol. 2008; 26: 3763-9.
20. Cella D., Michaelson M.D., Bushmakin A.G. et al.: Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon alpha in a phase III trial: final results and geographical analysis. Br. J. Cancer 2010; 102: 658-64.
21. Escudier B., Eisen T., Stadler W.M. et al.: Sorafenib in advanced cler-cell renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 125-34.
22. Bukowski R., Cella D., Gondek K. et al.: Sorafenib TARGETs Clinical Ttrial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am. J. Clin. Oncol. 2007; 30: 220-7.
23. Miyake H., Kurahashi T., Yamanaka K. et al.: Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU Int. 2010; 106: 1643-7.
24. Sternberg C.N., Davis I.D., Mardiak J. et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of randomized phase III trial. J. Clin. Oncol. 2010; 28: 1061-8.
25. NCT00720941. Study VEG108844, a study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma. Online: http://clinicaltrials.gov/ct2/show/NCT0072094 (Access: 14.12.2010).
26. Hudes G., Carducci M., Tomczak P. et al.: For the global ARCC Trial: Temsyrolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 2271-81.
27. Yand S., de Souza P., Alemao E. et al.: Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon alpha. Br. J. Cancer 2010; 116: 4256-60.
28. Motzer R.J., Escudier B., Quadard S. et al.: RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
29. Motzer R.J., Escudier B., Quadard S. et al.: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65.
30. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessement and cancer treatment guidelines. J. Clin. Oncol. 1996; 14: 671-9.
31. Velikova G., Booth L., Smith A.B. et al.: Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J. Clin. Oncol. 2004; 22: 714-24.
32. Motzer R.J., Mazumdar M., Bacik J. et al.: Effect of Cytokine Therapy on Survival for Patients with Advanced Renal Cell Carcinoma. J. Clin. Oncol. 2000; 18(9): 1928-35.
33. Heng D.Y., Xie W., Regan M. et al.: Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. J. Clin. Oncol. 2009; 27(34): 5794-9.
34. Lévy B.I.: Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor. Ann. Oncol. 2009; 20: 200-203.
2. Roila F., Cortesi E.: Quality of life as primary end point in oncology. Ann. Oncol. 2001; 12(supl.): S3-S6.
3. Feld R.: Endpoints in cancer clinical trials: Is there a need for measuring quality of life? Support Care Cancer 1995; 3: 23-7.
4. Casali P., Licitra L., Costntini M. et al.: Quality of life assessement and clinical decision-making. Ann. Oncol. 1997; 8: 1207-11.
5. Anderson R.T., Aaronson N.K., Bullinger M. et al.: A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research. Pharmacoeconomics 1996; 10: 336-55.
6. Maguire P., Selby P.: Assessing quality of life in cancer patients. B. J. Cancer 1989; 60: 437-40.
7. Bonomi A.E., Cella D.F., Hahn E.A. et al.: Multilingual translation of the Functional Assessement of Cancer Therapy (FACT) quality of life measurement system. Qual. Life Res. 1996; 5: 309-20.
8. Cella D., Hernandez L., Bonomi A.E. et al.: Spanish language translation and initial validation of the functional assessement of cancer therapy quality-of-life instrument. Med. Care 1998; 36: 1407-18.
9. Cella D.F., Tulsky D.S., Gray G. et al.: The Functional Assessement of Cancer Therapy scale: Development and validation of the general measure. J. Clin. Oncol. 1993; 11: 570-9.
10. Luckett T., King M.T., Butow P.N. et al.: Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann. Oncol. 2011; 22: 2179-90.
11. Cohen J.: Statistical power analysis for the behavioral Sciences. Wyd. 2. Materiały akademickie 1998.
12. Cella D.: Manual of the Functional Assessement of Chronic Illness Therapy (FACIT Scales), Version 4.1998. Evanston Northwestern Healthcare&Northwestern University Press, Center on Outcomes, Research and Education.
13. Brucker P.S., Yost K., Cashy J. et al.: General population and cancer patient norms for the Functional Assessement of Cancer Therapy – General (FACT-G). Eval. Health Prof. 2005; 28: 192-211.
14. Brazier J., Jones N., Kind P.: Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual. Life Res. 2004; 2: 169-80.
15. De Boer A.G., van Lanschott J.J., Stalmeier P.F. et al.: Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual. Life Res. 2004; 13: 311-320.
16. Rabin R., de Charro F.: EQ-5D: A measure of health status from the EuroQoL Group. Ann. Med. 2001; 33: 337-43.
17. Cella D., Yount S., Du H. et al.: Development and validation of the Functional Assessement of Cancer Therapy – Kidney Symptom Ondex (FKSI). J. Support Oncol. 2006; 4: 191-9.
18. Motzer R.J., Hutson T.E., Tomczak P. et al.: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 3584-90.
19. Cella D., Li J.Z., Cappelleri J.C. et al.: Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J. Clin. Oncol. 2008; 26: 3763-9.
20. Cella D., Michaelson M.D., Bushmakin A.G. et al.: Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon alpha in a phase III trial: final results and geographical analysis. Br. J. Cancer 2010; 102: 658-64.
21. Escudier B., Eisen T., Stadler W.M. et al.: Sorafenib in advanced cler-cell renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 125-34.
22. Bukowski R., Cella D., Gondek K. et al.: Sorafenib TARGETs Clinical Ttrial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am. J. Clin. Oncol. 2007; 30: 220-7.
23. Miyake H., Kurahashi T., Yamanaka K. et al.: Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU Int. 2010; 106: 1643-7.
24. Sternberg C.N., Davis I.D., Mardiak J. et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of randomized phase III trial. J. Clin. Oncol. 2010; 28: 1061-8.
25. NCT00720941. Study VEG108844, a study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma. Online: http://clinicaltrials.gov/ct2/show/NCT0072094 (Access: 14.12.2010).
26. Hudes G., Carducci M., Tomczak P. et al.: For the global ARCC Trial: Temsyrolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 2271-81.
27. Yand S., de Souza P., Alemao E. et al.: Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon alpha. Br. J. Cancer 2010; 116: 4256-60.
28. Motzer R.J., Escudier B., Quadard S. et al.: RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
29. Motzer R.J., Escudier B., Quadard S. et al.: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65.
30. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessement and cancer treatment guidelines. J. Clin. Oncol. 1996; 14: 671-9.
31. Velikova G., Booth L., Smith A.B. et al.: Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J. Clin. Oncol. 2004; 22: 714-24.
32. Motzer R.J., Mazumdar M., Bacik J. et al.: Effect of Cytokine Therapy on Survival for Patients with Advanced Renal Cell Carcinoma. J. Clin. Oncol. 2000; 18(9): 1928-35.
33. Heng D.Y., Xie W., Regan M. et al.: Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. J. Clin. Oncol. 2009; 27(34): 5794-9.
34. Lévy B.I.: Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor. Ann. Oncol. 2009; 20: 200-203.